Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ivosidenib or enasidenib plus intensive chemotherapy in newly diagnosed IDH1/IDH2-mutated AML or MDS-EB2
2018-000451-41Phase 3Active
- Sponsor
- HOVON
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivosidenib and enasidenib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (4 arms), sponsored by HOVON. Primary endpoint: Event-free survival. Started Oct 2018; status: active.
02
Drugs
ivosidenibenasidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2018-000451-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000451-41.